LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

LLY

1,007.46

+0.3%↑

JNJ

230.57

+0.93%↑

ABBV

211.37

+2.41%↑

UNH

400.75

+0.42%↑

AZN

185.67

+0.03%↑

Home・Lista de Ações・ResMed Inc

ResMed Inc

Abrir

SetorSaúde

202.38 -0.15

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

201.26

Máximo

204.42

Indicadores-chave
By Trading Economics
Rendimento	6.1M 399M
Vendas	8.6M 1.4B
P/E Médio do Setor	19.148 51.415
EPS	2.86
Rendimento de Dividendos	1.13
Margem de lucro	27.856
Funcionários	10,600
EBITDA	-67M 500M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+30.73% upside

Dividendos
By Dow Jones
Rendimento de Dividendos Médio do Setor	1.13% 2.34%
Próximos Ganhos	30 de jul. de 2026
Próxima data de dividendos	18 de jun. de 2026
Próxima data de ex-dividendo	14 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-3.5B 29B
Abertura anterior	202.53
Fecho anterior	202.38

Sentimento de Notícias

By Acuity

34%

66%

98 / 346 Ranking em Healthcare

ResMed Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

13 de mai. de 2026, 22:54 UTC

Ganhos

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 de mai. de 2026, 23:51 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 de mai. de 2026, 23:51 UTC

Conversa de Mercado

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 de mai. de 2026, 23:45 UTC

Conversa de Mercado

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 de mai. de 2026, 23:45 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

13 de mai. de 2026, 23:17 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 de mai. de 2026, 23:16 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 de mai. de 2026, 23:15 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 de mai. de 2026, 23:14 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 de mai. de 2026, 23:02 UTC

Conversa de Mercado

Ganhos

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 de mai. de 2026, 22:59 UTC

Conversa de Mercado

Ganhos

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 de mai. de 2026, 22:24 UTC

Ganhos

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 de mai. de 2026, 22:23 UTC

Ganhos

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 de mai. de 2026, 22:23 UTC

Ganhos

Xero FY International Revenue Growth 47%>XRO.AU

13 de mai. de 2026, 22:22 UTC

Ganhos

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 de mai. de 2026, 22:19 UTC

Ganhos

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 de mai. de 2026, 22:19 UTC

Ganhos

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 de mai. de 2026, 22:18 UTC

Ganhos

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 de mai. de 2026, 22:16 UTC

Ganhos

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 de mai. de 2026, 22:15 UTC

Ganhos

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 de mai. de 2026, 22:15 UTC

Ganhos

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 de mai. de 2026, 22:13 UTC

Ganhos

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 de mai. de 2026, 22:12 UTC

Ganhos

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 de mai. de 2026, 22:11 UTC

Ganhos

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 de mai. de 2026, 22:11 UTC

Ganhos

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 de mai. de 2026, 22:10 UTC

Ganhos

Xero Did Not Declare a Dividend>XRO.AU

13 de mai. de 2026, 22:10 UTC

Ganhos

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 de mai. de 2026, 22:09 UTC

Ganhos

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 de mai. de 2026, 22:00 UTC

Ganhos

Cisco to Shed Jobs for All-In AI Push -- Update

13 de mai. de 2026, 21:11 UTC

Ganhos

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Comparação entre Pares

Variação de preço

ResMed Inc Previsão

Preço-alvo

By TipRanks

30.73% parte superior

Previsão para 12 meses

Média 264.56 USD 30.73%

Máximo 340 USD

Mínimo 225 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para ResMed Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

13 ratings

Comprar

Manter

Vender

Com base em 13 analistas que deram avaliações de ações para ResMed Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

98 / 346 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre ResMed Inc

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.